Solutions for burn care - clinical evidence highlights
Cost effectiveness with Mepilex Ag in the treatment of burns
An open, parallel, randomised, comparative, multi-centre investigation evaluating the cost effectiveness, efficacy, safety and tolerance of Mepilex® Ag versus Silvadene® in the treatment of partial thickness burns1.
To determine if the introduction of a new dressing regime for partial-thickness thermal burns could improve healing outcomes and reduce treatment costs.
A randomised, multi-centre trial was conducted to compare the efficacy and cost effectiveness of Mepilex Ag with Silvadene (silver sulfadiazine cream) in the treatment of partial-thickness thermal burns. Data collection took place at initiation (<36 hours post-burn) and at assessment days 7, 14, 21, with follow-up at day 35 where wound assessment and pain measurements were undertaken.
The Mepilex Ag group (n=49) provided faster healing times, reduced hospital stay and required fewer dressing changes, compared to the Silvadene group (n=51). Differences in pain intensity, in favour of Mepilex Ag, were noted at application, during wear-time and on removal during the initial post-burn period. Mean total cost of therapy per patient was $309 for the Mepilex Ag group and $514 for the Silvadene group.
Mepilex Ag showed clinical and health economic benefits. The new treatment regime performed better clinically, and also achieved significant reductions in healthcare costs.